Abstract:BACKGROUND: The lack of new anthelmintic agents is of growing concern because it affects human health and our food supply, as both livestock and plants are affected. Two principal factors contribute to this problem. First, nematode resistance to anthelmintic drugs is increasing worldwide and second, many effective nematicides pose environmental hazards. In this paper we address this problem by deploying a high throughput screening platform for anthelmintic drug discovery using the nematode Caenorhabditis elegans as a surrogate for infectious nematodes. This method offers the possibility of identifying new anthelmintics in a cost-effective and timely manner.METHODS/PRINCIPAL FINDINGS: Using our high throughput screening platform we have identified 14 new potential anthelmintics by screening more than 26,000 compounds from the Chembridge and Maybridge chemical libraries. Using phylogenetic profiling we identified a subset of the 14 compounds as potential anthelmintics based on the relative sensitivity of C. elegans when compared to yeast and mammalian cells in culture. We showed that a subset of these compounds might employ mechanisms distinct from currently used anthelmintics by testing diverse drug resistant strains of C. elegans. One of these newly identified compounds targets mitochondrial complex II, and we used structural analysis of the target to suggest how differential binding of this compound may account for its different effects in nematodes versus mammalian cells.CONCLUSIONS/SIGNIFICANCE: The challenge of anthelmintic drug discovery is exacerbated by several factors; including, 1) the biochemical similarity between host and parasite genomes, 2) the geographic location of parasitic nematodes and 3) the rapid development of resistance. Accordingly, an approach that can screen large compound collections rapidly is required. C. elegans as a surrogate parasite offers the ability to screen compounds rapidly and, equally importantly, with specificity, thus reducing the potential toxicity of these compounds to the host and the environment. We believe this approach will help to replenish the pipeline of potential nematicides.

An Efficient and Novel Screening Model for Assessing the Bioactivity of Extracts Against Multidrug-Resistant Pseudomonas Aeruginosa Using Caenorhabditis Elegans.

Establishment of an infection model using Caenorhabditis elegans-multidrug resistance P. aeruginosa

Establishment of an Antibiotic Screening Model Using Caenorhabditis Elegans

An Integrated Microfluidic Platform for Evaluating in Vivo Antimicrobial Activity of Natural Compounds Using a Whole-Animal Infection Model.

New tools to monitor Pseudomonas aeruginosa infection and biofilms in vivo in C. elegans

An update on the use of C. elegans for preclinical drug discovery: screening and identifying anti-infective drugs

Establishment of Antimicrobial Screening Experiment System for Caenorhabditis Elegans

Recent progress of Caenorhabditis elegans:as host model and tool for antimicrobial drug screening

A novel high-throughput nematicidal assay using embryo cells and larvae of Caenorhabditis elegans.

High-Throughput Identification Of Antibacterials Against Pseudomonas Aeruginosa

A High-throughput Assay for the Prediction of Chemical Toxicity by Automated Phenotypic Profiling of Caenorhabditis elegans

Host cell-based screening assays for identification of molecules targeting Pseudomonas aeruginosa cyclic di-GMP signaling and biofilm formation

Using C. elegans Forward and Reverse Genetics to Identify New Compounds with Anthelmintic Activity

A Rapid Phenotypic Whole-Cell Screening Approach for the Identification of Small-Molecule Inhibitors That Counter β-Lactamase Resistance in Pseudomonas aeruginosa.

Application of the Luminescent Luxcdabe Gene for the Rapid Screening of Antibacterial Substances Targeting Pseudomonas Aeruginosa

A novel assay for drug screening that utilizes the heat shock response of Caenorhabditis elegans nematodes

The Use of Caenorhabditis Elegans Model to Screen Lactobacilli for the Control of Patulin

Preliminary Acute Toxicity Assessment of Pharmaceutical Compounds by Caenorhabditis Elegans

Protocol for Survival Assay of Caenorhabditis Elegans to Pseudomonas Aeruginosa PA14 Infection

A high-throughput microplate toxicity screening platform based on Caenorhabditis elegans

Using Caenorhabditis elegans is to study the antitumor drug screening model of the Ras/MAPK signaling pathway